Revue des Maladies Respiratoires Actualités, Год журнала: 2023, Номер 15(2), С. 2S209 - 2S213
Опубликована: Окт. 1, 2023
Journal of Clinical Oncology, Год журнала: 2024, Номер 42(14), С. 1699 - 1721
Опубликована: Март 18, 2024
To guide the vaccination of adults with solid tumors or hematologic malignancies.
Язык: Английский
Процитировано
25
Biomedicines, Год журнала: 2024, Номер 12(1), С. 217 - 217
Опубликована: Янв. 18, 2024
Immunotherapy is now established as a potent therapeutic paradigm engendering antitumor immune response against wide range of malignancies and other diseases by modulating the system either through stimulation or suppression components such CD4+ T cells, CD8+ B monocytes, macrophages, dendritic natural killer cells. By targeting several checkpoint inhibitors blockers (e.g., PD-1, PD-L1, PD-L2, CTLA-4, LAG3, TIM-3) expressed on surface monoclonal antibodies polyclonal have been developed already translated clinically. In addition, cell-based, CAR cell therapies also shown to be promising effective immunotherapeutic approaches. particular, therapy has benefited from advancements in CRISPR-Cas9 genome editing technology, allowing generation modified cells with enhanced immunity. However, emerging SARS-CoV-2 infection could hijack patient’s releasing pro-inflammatory interleukins cytokines IL-1β, IL-2, IL-6, IL-10, IFN-γ TNF-α, respectively, which can further promote neutrophil extravasation vasodilation blood vessels. Despite significant development advanced technologies, after certain period treatment, cancer relapses due resistance immunotherapy. Resistance may primary (where tumor do not respond treatment), secondary acquired develop gradually ICIs therapy). this context, review aims address existing technologies mechanisms drugs, explain impact COVID-19 treatment. we will discuss what future implementation these strategies drug resistance. Finally, emphasize practical steps lay groundwork for enlightened policy intervention resource allocation care patients.
Язык: Английский
Процитировано
10
Journal for ImmunoTherapy of Cancer, Год журнала: 2024, Номер 12(4), С. e008151 - e008151
Опубликована: Апрель 1, 2024
We describe three cases of critical acute myositis with myocarditis occurring within 22 days each other at a single institution, all 1 month receiving the initial cycle anti-PD-1 drug pembrolizumab. Analysis T cell receptor repertoires from peripheral blood and tissues revealed high degree clonal expansion public clones between cases, several expanded skeletal muscle putatively recognizing viral epitopes. All patients had recently received COVID-19 mRNA booster vaccine prior to treatment were positive for SARS-CoV2 Spike antibody. In conclusion, we report series unusually severe following PD-1 blockade vaccination.
Язык: Английский
Процитировано
5
Journal for ImmunoTherapy of Cancer, Год журнала: 2024, Номер 12(1), С. e007922 - e007922
Опубликована: Янв. 1, 2024
Background The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant is highly transmissible and evades pre-established immunity. Messenger RNA (mRNA) vaccination against ancestral strain spike protein can induce intact T-cell immunity the variant, but efficacy of booster in patients with late-stage lung cancer on immune-modulating agents including anti-programmed cell death 1(PD-1)/programmed death-ligand 1 (PD-L1) has not yet been elucidated. Methods We assessed responses using a modified activation-induced marker assay, coupled high-dimension flow cytometry analyses. Peripheral blood mononuclear cells (PBMCs) were stimulated various viral peptides antigen-specific evaluated cytometry. Results Booster vaccines induced CD8 + response SARS-CoV-2 both non-cancer subjects cancer, only marginal induction was detected for CD4 T cells. Importantly, from showed distinct subpopulation dynamics varying degrees differentiation compared subjects, evidence dysfunction. Notably, female-biased observed. Conclusion conclude that immunotherapy show substantial qualitative deviation their to mRNA vaccines, highlighting need heightened protective measures minimize risk breakthrough infection other future variants.
Язык: Английский
Процитировано
4
Therapeutic Advances in Medical Oncology, Год журнала: 2025, Номер 17
Опубликована: Янв. 1, 2025
Therapeutic cancer vaccines aim to generate a robust immune response against tumour-associated antigens (TAAs) or tumour-specific antigens. While their safety is well established, efficacy as monotherapy remains limited due factors such self-tolerance TAAs and the immunosuppressive tumour microenvironment. Combining with systemic anticancer therapies (SACTs) offers promising strategy improve efficacy. However, optimal timing combination checkpoint inhibitors (ICIs) chemotherapy enhance immunogenicity are not yet fully understood. This review aims assess evidence regarding of antiviral when combined SACTs, including ICIs, particular focus on vaccine administration relative SACT. Additionally, we evaluate impact steroids immunogenicity. Our findings suggest that critical, improved immunogenic responses observed administered at nadir (15 days post-chemotherapy). Certain chemotherapies, low-dose metronomic cyclophosphamide paclitaxel, demonstrate potential for immunomodulation, enhancing T-cell vaccines. Conversely, may reduce The ICIs shows synergistic effect, concurrent generally yielding better outcomes than sequential approaches. Prospective trials exploring various timings sequences essential optimize
Язык: Английский
Процитировано
0
BMC Immunology, Год журнала: 2025, Номер 26(1)
Опубликована: Апрель 16, 2025
Язык: Английский
Процитировано
0
Journal for ImmunoTherapy of Cancer, Год журнала: 2024, Номер 12(1), С. e008233 - e008233
Опубликована: Янв. 1, 2024
Background Despite immunization, patients on antineoplastic and immunomodulating agents have a heightened risk of COVID-19 infection. However, accurately attributing this to specific medications remains challenging. Methods An observational cohort study from December 11, 2020 September 22, 2022, within large healthcare system in San Diego, California, USA was designed identify associated with greatest postimmunization SARS-CoV-2 Adults prescribed WHO Anatomical Therapeutic Chemical (ATC) classified were matched (by age, sex, race, number immunizations) control not these yielding population 26 724 for analysis. From population, 218 blood samples collected an enrolled subset assess serological response cytokine profile relation immunization. Results Prescription ATC immunomodulatory elevated infection (HR 1.50, 95% CI 1.38 1.63). While multiple immunization doses demonstrated decreased association risk, treated four remained at 1.23, 1.06 1.43). Risk variation identified among medication subclasses, PD-1/PD-L1 inhibiting monoclonal antibodies, calcineurin inhibitors, CD20 antibody inhibitors associate increased Antineoplastic also displayed reduced IgG epitopes alongside unique serum profile. Conclusions drug-specific manner. This comprehensive, unbiased analysis all identifies risk. These findings are crucial guiding refining vaccination strategies treatments, ensuring optimized protection susceptible future variant surges potentially other RNA targets.
Язык: Английский
Процитировано
3
Cell Death and Disease, Год журнала: 2023, Номер 14(6)
Опубликована: Июнь 30, 2023
Abstract Cancer patients are susceptible to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Different antitumor treatments have attracted wide attention in the context of coronavirus disease 2019 (COVID-19), especially immune checkpoint inhibitors (ICIs) that revolutionized oncology changes. It may also protective and therapeutic roles viral infections. In this article, we collected 26 cases SARS-CoV-2 infection during ICIs therapy 13 related COVID-19 vaccination from Pubmed, EMBASE, Wed Science. Of these cases, 19 (73.1%) presented mild 7 (26.9%) were cases. Melanoma (47.4%) was a common cancer type lung (71.4%) ( P = 0.016). The results showed their clinical outcomes varied widely. Although there similarities between pathway immunogenicity, overactivated T cells, which often leads immune-related adverse events. fact, vaccine has been shown be safe effective treated with ICIs. review, report vital observations or explore potential interaction them.
Язык: Английский
Процитировано
8
Frontiers in Immunology, Год журнала: 2024, Номер 15
Опубликована: Авг. 27, 2024
Introduction Research has confirmed the safety and comparable seroconversion rates following SARS-CoV-2 vaccination in patients with solid cancers. However, impact of cancer treatment on vaccine-induced T cell responses remains poorly understood. Methods In this study, we expand previous findings within VOICE trial by evaluating functional phenotypic composition mRNA-1273-induced tumors undergoing immunotherapy, chemotherapy, or both, compared to individuals without cancer. We conducted an ELISpot analysis 386 participants assess spike-specific 28 days after full vaccination. Further in-depth characterization using flow cytometry was performed a subset 63 analyze phenotype differentiation state responses. Results showed robust induction across all groups, response ranging from 75% 80%. Flow revealed distinctive cytokine production pattern cohorts, CD4 cells producing IFNγ, TNF, IL-2, CD8 CCL4. Variations were observed proportion monofunctional particularly higher treated chemotherapy alone, while those immunotherapy chemoimmunotherapy predominantly produced IFNγ. Despite these differences, polyfunctional memory cohorts. Notably, immunotherapy-treated exhibited expansion terminally differentiated effector phenotype. Discussion These demonstrate that systemic does not compromise quality This underscores importance COVID-19 cancers treatment.
Язык: Английский
Процитировано
2
JCO Oncology Practice, Год журнала: 2024, Номер 20(7), С. 889 - 892
Опубликована: Март 18, 2024
Язык: Английский
Процитировано
1